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ABSTRACT 
Objectives: The aim of this study was to demonstrate the effect of a novel permeation 
enhancer system using two existing marketed nail lacquers and the delivery of terbinafine 
through human nail samples in vitro.  
Methods: Initially a modified Franz cell was used, where sections of human nail serve as the 
barrier through which drug penetrates into an agar filled chamber infected with 
dermatophytes. A second study was performed using a novel infected nail model where 
dermatophytes are incubated with and grow into human nail and ATP levels are used as 
biological marker for antimicrobial activity. 
Key Findings: The novel permeation enhancing system, increased the permeation of both 
existing drugs formulated in nail lacquers and terbinafine through human nail sections 
mounted in modified Franz cell. Furthermore the ATP assay confirmed that the system also 
enhanced the permeation of terbinafine through infected cadaver nail resulting in a decrease 
in ATP levels equivalent to those of uninfected negative control samples.  
Conclusions: This study has clearly demonstrated that the use of a novel permeation 
enhancing system, which fundamentally alters the chemical structure of the nail not only 
enhances the efficacy of the existing topical formulations but enables the delivery and efficacy 
of terbinafine when applied ungually.  Such a topically applied system has the possibility of 
overcoming the  systemic side effects when terbinafine is delivered orally. 
 
Key Words: nail, permeation enhancer, ungual, onychomycosis, terbinafine 
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INTRODUCTION 
Onychomycosis is a fungal infection of the nail that accounts for approximately 50% of all nail 
disorders and affects toenails substantially more than fingernails [1]. The prevalence of 
onychomycosis has been estimated at around 5% in Western countries and has continued to increase 
in recent decades [2-8]. While onychomycosis may be caused by dermatophytes, yeasts or moulds it 
is accepted that the former are by far the predominant pathogens and probably account for more than 
85% of all cases of fungal nail infections. Of the dermatophytes the most common cause of 
onychomycosis is Trichophyton rubrum (T.rubrum) [5, 9]. Causative moulds include Scopulariopsis 
brevicaulis and Scytaldium dimidiatum. 
Distal and lateral subungual onychomycosis (DLSO) is the commonest type of onychomycosis.  
Infection is initially a disease of the hyponichium, resulting in hyperkeratosis of the distal nail bed.  It 
generally begins at the lateral edge of the nail rather than the central portion and spreads 
progressively proximally down the nail bed producing hyperkeratosis and thus onycholysis.  Ultimately 
the underside of the nail is involved which results in thickening of the nail.  The nail may become 
friable and crumbles away.  Sometimes the fungus proliferates in the space between the nail plate 
and nail bed (known as a dermatophytoma) [10] and is often the cause of treatment failure [3].  
It is important to treat onychomycosis, as it is an infection that does not resolve spontaneously.  The 
infection may worsen, spread to other uninfected locations (other nails or to the surrounding skin) or 
infect other patients.  Infections of the fingernails may be cosmetically unacceptable. Infections of the 
toenail can greatly affect the quality of life of patients and cause pain and morbidity [9].   
Treatment for onychomycosis may be topical or oral. There have been four main oral therapies 
available for the treatment of onychomycosis.  These are griseofulvin (Grisovin
®
, Glaxo Welcome) 
ketoconazole (Nizoral
®
, Janssen-Cilag), itraconazole (Sporanox
®
, Janssen-Cilag) and terbinafine 
(Lamisil
®
, Novartis).  Griseofulvin has been available since the 1950’s and due to its fungistatic activity 
against dermatophytes requires long treatment periods (9-12 months for toenail infections) with low 
cure rates and high relapse rates [11, 12].  Ketoconazole was the first imidazole introduced for the 
treatment of onychomycosis in the 1980’s.  However, due to hepatotoxicity its use is now restricted to 
fingernail infections that have failed to respond to other therapies. The newer antifungals, itraconazole 
and terbinafine, are highly effective in the treatment of onychomycosis with mycological cure rates of 
70-80% and treatment periods of 12-16 weeks [12-14]. The main disadvantages of systemic oral 
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treatments is that they can cause systemic toxicity and may also cause significant drug interactions so 
it is important to review and document concomitant medications prior to commencing treatment [13, 
15]. 
Topical therapies include amorolfine (Loceryl
®
, Galderma) and ciclopirox (Penlac
®
, Dermik) [16-20].  
Probably as a result of the poor drug penetration from these products through the nail, treatment 
times are long (12 months for toenail infections) and cure rates are low [3, 12, 21] and alternative 
drugs and formulations to improve delivery are being sought. 
Permeation of drugs through the skin has been extensively documented in the last 60 years [22-29], 
while permeation of drugs through the nail remains a relatively undocumented area. In comparison to 
the thin Stratum corneum, the much thicker nail plate means a much longer diffusional pathway for 
drug delivery. In addition, in contrast to the elastic and pliable Stratum corneum, the nail plate is 
dense and hard. However, when the thickness difference is taken into consideration, the water 
permeation rate of the nail is ca. 10 times higher than that of the Stratum corneum. As such it would 
be expected that the permeation characteristics of the nail are very different from the Stratum 
corneum, which is supported by the current literature [3, 30].  
The physical and chemical differences between the nail and Stratum corneum, are probably the 
reasons for the lack of efficacy of topical nail antifungal formulations presently on the market as they 
have been developed based on knowledge of the barrier properties of the skin. Thus, when designing 
topical formulations for perungual drug absorption it is essential to consider the physicochemical 
properties of the drug molecule (e.g. size, shape, charge log P etc), the formulation characteristics 
(e.g. vehicle, pH drug concentration), possible penetration enhancers, as well as any possible 
interactions between the drug and keratin. Monti et al showed that incorporation of the water soluble 
film forming agent hydroxypropyl chitosan (HPCH) in a nail lacquer resulted in a decreased lag time in 
the uptake of ciclopirox compared to Penlac
®
. The authors suggested that this was likely to be due to 
the adhesive properties of HPCH when in contact with biological membranes, and the formation of 
hydrogen bonds between the hydroxypropyl groups on the HPCH and the keratin resulting in intimate 
contact between the vehicle and the keratin matrix thus enhancing transfer of ciclopirox from the 
vehicle in to the nail matrix [31].  Malhotra and Zatz investigated a wide range of possible nail 
permeation enhancers using tritiated water as a probe. They postulated that any potential permeation 
enhancer would induce changes in the primary or higher order structure of keratin thus making the 
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nail more permeable. Molhotra and Zatz tested a wide range of compounds including mercaptan 
compounds, sulfites and bisulfites, keratolytic agents and surfactants. They concluded that the most 
effective enhancing agents produced irreversible changes to the keratin matrix compromising its 
barrier function, where as those compounds that were not as effective produced minor reversible 
changes to the barrier function that was quickly restored [32].  A range of non-chemical physical 
enhancement techniques, including abrasion or etching of the nail surface, ultrasound and 
micropration have also been investigated by a range of authors and are comprehensively reviewed 
elsewhere [33]. 
Described in this paper is a novel penetration enhancer consisting of sequential application of a 
reducing agent and an oxidising agent used as a pre-treatment prior to application of a 
pharmaceutically active agent. Khengar et al., previously tested a range of reducing and oxidising 
agents using a nail swelling model to predict the enhancing effect of such agents [34]. The authors 
identified thioglycolic acid and urea hydrogen peroxide as being the reducing and oxidising agents 
which produce the greatest level of enhancement of those tested. Brown et al. subsequently tested 
the enhancing potential of these agents alone and in combination with each other and discovered that 
treatment of the nail with thioglycolic acid followed by urea hydrogen peroxide had the greatest 
penetration enhancing effect on a range of model permeants [35]. This pre-treatment (thioglycolic acid 
followed by hydrogen peroxide) is not a product on its own, it has no therapeutic effect and contains 
no active ingredients, it is a penetration enhancer that has the capability to alter the barrier properties 
of the nail such that it becomes more permeable to antifungal agents such as ciclopirox, amorolfine 
and terbinafine. 
This study aims to demonstrate the effect of a novel penetration enhancing system on the permeation 
of two drugs, amorolfine and ciclopirox presented in two marketed nail lacquers and terbinafine 
applied in a spray system developed in house.  
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MATERIALS AND METHODS 
TA and urea hydrogen peroxide addition compound (urea H2O2) were purchased from Sigma-Aldrich 
(Dorset, UK). Human nail clippings were donated from healthy volunteers, and cadaver nails obtained 
from a human tissue bank (Science Care Anatomical, AZ. USA) following approval by the King’s 
College Research Ethics Committee – (study ref no. 04/05-126). Validated ChubTur and TurChub
®
 
permeation cells were kindly donated by MedPharm Ltd. Ethanol (EtOH) was purchased from BDH 
Chemicals Ltd (Dorset, UK). Acetonitrile (ACN), Triethylamine, orthophosphoric acid, potassium 
dihydrogen orthophosphate (KH2PO4) and Ringers solution were supplied by Fisher (Leicestershire, 
UK). Triethylamine, orthophosphoric acid and potassium dihydrogen orthophosphate (KH2PO4) were 
supplied by Fisher (Leicestershire, UK), MedPharm’s lysing agent was supplied by MedPharm Ltd., 
T.rubrum was originally isolated from a patient suffering from onychomycosis and was a gift from 
Cardiff University, sterile gauze filter (Propax, 7.5cm x 7.5 cm 8 ply gauze swab, BP Type 13) was 
obtained from Smith&Nephew. Adenosine 5-triphosphate standard disodium salt trihydrate 
substantially vanadium free was obtained from Sigma (Poole, UK). BacTiter-Glo kit and BacTiter Glo 
substrate were obtained from Promega (Southampton, UK).  
 
TurChub assay 
The TurChub
®
 assay uses a modified Franz-cell, where sections of human nail serve as the barrier 
through which the drug initially penetrates through into an agar filled receptor chamber where the 
dermatophytes (T.rubrum) grow. The cells are dosed with the test formulation and then incubated for 
a set period of time, at a set temperature. After incubation the presence of any zone of inhibition is 
measured (examples of which are shown in figure 1).  
 
Preparation of human nail clippings (distal) 
Initially, distal nail clippings were obtained from volunteers toe nails, which had been grown to a 
minimum length of 3 mm. All volunteers were required to not have used nail varnish or polish on their 
toe nails within 6 months and have not shown any signs of disease to their nails within 6 months.  All 
volunteers were asked to remove the distal nail sections using either scissors or standard nail 
clippers. The nail clippings were then placed into an appropriate container e.g. plastic bag, vial, 
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envelope etc for transfer to our laboratory. The nail clippings were then placed into an 8 ml bijou bottle 
per donor/donation and labeled with any details supplied. 
 
Preparation of 3mm x 3mm distal nail segments 
Using scissors, the nails clippings were cut into pieces, which were a minimum of 3 mm by 3 mm. The 
nail clippings were immersed into a 70% ethanol in water solution and vortex mixed for one minute. 
The ethanol solution was then decanted and replaced with a fresh 70 % ethanol solution and vortex 
mixed for a further minute. The ethanol solution was then decanted and replaced with Ringer’s 
solution, vortex mixed for one minute and decanted and replaced with fresh Ringer’s. This process of 
washing with Ringer’s was carried out a total of three times, replacing the wash solution at each 
phase. Once the washing process was complete, the nail clippings were placed into a sterile Petri 
dish without a lid and air dried under a laminar flow cabinet for 30 minutes at room temperature. Once 
the nail clippings were dry, they were placed into new 8 ml bijou bottles (separate bottle per donor, 
per batch). Nails were measured for thickness using a sterilized pair of calipers. 
 
Preparation of Standard Sabouraud dextrose agar (SDA) 
Briefly, 65 g of the powdered agar was suspended in 1 litre of distilled water. The mixture was then 
heated to boiling point whilst stirring to dissolve the powdered agar completely. The agar solution was 
then sterilised in an autoclave for 15 minutes at 121°C. 
 
Preparation of Potato dextrose agar (PDA) 
Briefly, 39 g of the powdered agar was suspended in 1 litre of purified water. The mixture was then 
heated to boiling point whilst stirring to dissolve the powdered agar completely. The agar solution was 
then sterilised in an autoclave for 15 minutes at 121°C. 
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Preparation of a suspension of Trichophyton rubrum 
T. rubrum which was originally isolated from a patient suffering from onychomycosis was sub cultured 
onto fresh Sabouraud dextrose agar slopes and reference samples were placed into a glycerol 
solution and cryogenically frozen. Isolates of the dermatophytes were also transferred into Ringer’s 
solution and onto potato dextrose agar and incubated
 
at 28°C for 7 days using the previously tested 
procedure to produce conidia. The fungal colonies were then covered with
 
5 ml of Ringer’s solution 
and suspensions made by gently probing the surface with the tip of a Pasteur
 
pipette, generating a 
mixture of conidial and hyphal fragments. The spore suspension was then filtered through sterile 
gauze (Smith+Nephew, Propax, 7.5cm x 7.5 cm 8 ply gauze swab, BP Type 13) to remove mycelium. 
The densities of
 
the suspension was assessed using a UV spectrophotometer at 600 nm, and the 
Spore suspension adjusted until a spore count of approximately 1 x 10
7 
cfu/ml was achieved by 
diluting with Ringer’s solution. A serial dilution of the final spore suspension and plate count was also 
carried out for confirmation. The identity of the isolated strain was verified by microscopy and culture 
on agar. 
 
Preparation of TurChub cells 
The receiver compartment of the TurChub
 
was filled with a pre-determined calibrated volume of 
Sabouraud dextrose agar. The agar was then inoculated with 50 l of previously prepared T. rubrum 
suspension. Nail clippings (approximate size: 3mm x 3mm) were mounted into the validated 
TurChub
®
 gasket system, to ensure no leakage of formulation around the nail. The gasket system 
was then mounted into the TurChub
®
 cell ensuring complete contact with the agar in the receiver 
compartment and clamped in place between the donor and receiver compartments. An initial 
feasibility study was performed to determine the relative efficacies of Penlac
®
 and Loceryl
®
 when 
applied to human nail in the TurChub
®
 cells. The nail sections used in this study were cut to a uniform 
thickness of 5 µm using a microtome. The nail lacquers (0.5 ml) were applied to the apical surface of 
the nail, the cells occluded with Parafilm
®
 and incubated at 25°C for 7 days.  
The main study was performed using full thickness human nails in order to closely mimic the in vivo 
situation in a patient suffering from onychomycosis. In this study the nails were dosed with the novel 
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dual system penetration enhancers prior to application of the same nail lacquers used in the feasibility 
study. Penetration enhancer 1 (PE1) was 5% TA (w/w) prepared in 20% EtOH: Water  (v/v). 
Penetration enhancer 2 (PE2) was Urea H2O2 solution was prepared in water (Millipore) such that the 
concentration of the H2O2 was 15% (w/v). Cells were dosed with PE1 by applying 0.5 ml to the donor 
compartment of the ChubTur
®
 cell so that the apical surface of the nail was submerged. Following a 
period of 20 h, the PE1 solution was removed and the donor compartment flooded 3 times with water 
to wash away any residual PE. Any remaining moisture was removed using a dry tissue. PE2 was 
then applied in the same way and after 20 h, PE2 was again washed out of the donor chamber and 
any excess solution was removed using a dry tissue. The relevant nail lacquer was applied (0.5 ml) to 
the dry clean donor compartment after the application of the PEs. The diffusion cells were then sealed 
with Parafilm™ to prevent evaporation and incubated for 7 days. A set of control cells in which no 
penetration enhancer was applied before the nail lacquers were also prepared in the same way.  
 
Infected Nail Model 
 
A second study was performed using a novel infected nail model developed by MedPharm Ltd. In this 
infected nail model, ATP levels were used as biological marker for antimicrobial activity across human 
cadaver nails and distal nail clippings. Each nail was stored in an individual bag in a freezer prior to 
use. Prior to cutting the full cadaver nails into 3 mm x 3 mm segments, the nails were removed from 
the freezer (leaving them in the individual sealed bags) and placed in a laminar flow cabinet for 30 
min to defrost. The cadaver nail was then placed into a sterile universal tube prior to cutting into 
segments. As the thickness, rigidity and permeability of cadaver nails varies across the entire nail, 
only the distal section of the cadaver nails was used. The underside of the nail was also irregular, and 
all loose material was removed where possible, by gently scraping with the scalpel blade. The nails 
were then sterilised by brief immersion in 70% ethanol, washing in ringers solution and gently heating 
to 60°C for 15 minutes. A pair of sterile callipers were used to measure the length (in mm) and width 
(in mm) of the sterile cadaver nail, in order to determine how many 3 x 3 mm sections could be 
obtained and these were cut using a scalpel. Each nail segment was designated a number to 
maintain traceability. The thickness of the nail segments were then individually measured using 
callipers. Distal nail clippings were prepared as detailed above.  The underside of the nails were 
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initially inoculated with T. Rubrum (5µl of 1 x 10
7 
cfu/ml) and incubated under controlled temperature 
and humidity to stimulate growth of the organism on and into the nails. Sacrificial samples were set up 
to monitor the growth of the organism on the nail samples over the incubation period, and control nails 
without any organisms were also set up and incubated to ensure no contamination. After establishing 
the growth of the organisms on the nails, the nails were dosed with one of the test formulations as 
detailed below. The performance of the formulation was determined after removing the nail sample 
from the cell and recovering viable microorganisms using a previously validated bioluminescence ATP 
method. 
 
Dosing regime. 
As a result of the data obtained in the TurChub study it was decided the infected nail model would be 
used to compare the efficacy of both the commercial products (Loceryl
®
 and Penlac
®
) to a spray 
product containing terbinafine developed in-house and a range of controls. The terbinafine spray, was 
formulated by adding terbinafine (1%) to the urea hydrogen peroxide (0.5%) component of the pre-
treatment enhancing system, in a co-solvent (15% ethanol) to which a film forming agent 
(copovidone) was also added prior to addition of hydroflourolkane as the propellant.   After the 14 day 
incubation period one group of infected nails were removed from the incubator and dosed with 1 
actuation of Thioglycolic acid spray formulation and returned to the incubator for 8 hours. After this 
period, the Thioglycolic acid spray formulation was washed off using sterilized water and wiped using 
a sterile cotton swab. Then 1 actuation of the Urea hydrogen peroxide spray formulation also 
containing the active (terbinafine), or a placebo formulation containing only Urea hydrogen peroxide, 
was applied to the nail surface. 
A second group of infected nails were dosed with either Penlac
®
 or Loceryl
®
 only (1 l, this volume 
was calculated proportionally for the size of the nail clipping based on the directions in the patient 
information leaflet for application to an infected nail in vivo), while a third set were used as an 
inoculated only control and received no further treatment. Following dosing, all cells were placed back 
into the incubator for a further 7 days. Three weeks after initial inoculation with T.rubrum, all cells 
were removed from the incubator dismantled and analysed for the presence of ATP. Whereby the 
nails were aseptically removed from the ChubTur
®
 cells and placed into a 96 well Nunc micro titre 
plate. The micro titre plate was then placed in the fluorescence plate reader, whereby Bactitre-glo, 
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containing the lysing agent is added by automated injection at set intervals and the fluorescence 
measured after a pre-determined period of time to ensure consistency and complete lysis of all viable 
organism. 
 
ATP assay – calibration 
ATP calibration standards of known concentrations (0, 1, 5, 10, 25, 50, 100 and 200 ng/ml) were 
prepared by diluting the stock ATP standard (1 mg/ml), sequentially, in water.  These standards (100 
l) were then aliquoted into a sterile Nunc 96 well white micro-titre plate followed by the addition of 
100 l of the MedPharm lysing agent and Promega BacTiter-Glo ™ assay reagent.  The solution was 
mixed for a period of 30 sec and the total amount of light that was emitted from the well measured 
every 10 sec over a total period of 10 min using Biotek FLx800 micro-titre fluorimeter/luminometer.  
The average of the relative light units measured over the 10 min was then calculated.   
 
Statistical analysis 
Statistical analysis of the effect of pre-treatment with the enhancing system on the efficacy 
(demonstrated by level of ATP activity) of Penlac
®
, Loceryl
®
 and the terbinafine spray formulation 
compared to positive and negative controls was evaluated using the Kruskal-Wallis test. A 
significance level of P < 0.05 denoted significance in all cases. In all cases the number of replicates 
was 5. 
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 RESULTS AND DISCUSSION 
 
TurChub
®
 Assay 
The initial study was performed using nail samples cut to a uniform thickness of 5 µm using a 
microtome. In this study a small zone of inhibition was detected following a single application of 
Penlac
®
 (3.7 ± 5.7%, mean ± SD) and a larger zone of inhibition following a single application of 
Loceryl
®
 (93.7 ± 4.6%, mean ± SD).  A secondary study was performed using full thickness human 
nail sections, in this study no zone of inhibition was detected for either Penlac
®
 (0.00 ± 0.00%) or 
Loceryl
®
 (0.00 ± 0.00%).  Penlac
®
 and Loceryl
®
 were also applied to the full thickness nail sections 
following an initial pre-treatment with the permeation enhancing system. Following this pre-treatment 
a significantly increased zone of inhibition was detected for both commercial formulations (pre-
treatment + Penlac
®
 100 ± 0.00%,  pre-treatment + Loceryl
®
  46.5 ± 6.3%) through full thickness nail 
samples. Indeed the pre-treatment followed by application of Penlac
®
 resulted in complete kill in all 
replicates of the sample such that there was no detectable presence of T. rubrum in the cell and the 
samples were identical to the negative control samples that were uninfected (100 ± 0.00%) (figure 2).  
 
Data from the initial study using 5 µm nail sections indicates that one application of Loceryl alone 
appears to be a more potent treatment for onychomycosis than Penlac using this model. However in 
the second part of the study using full thickness nail sections neither Loceryl or Penlac 
demonstrated any efficacy against T.rubrum. This implies that in an in vivo situation, where 
penetration of the full thickness of the nail would be required in order to guarantee complete cure, 
both Penlac and Loceryl would perform poorly. However, this may be an unfair comparison as each 
lacquer was only applied once in this study as opposed to the repeated applications (Loceryl
®
 1-2 
times per week until the nail has grown out and Penlac
®
 daily until the nail has grown out) indicated in 
their use for the treatment of onychomycosis. Also patient instructions for the use of both Loceryl
®
 and 
Penlac
®
 involve debridement and cleaning of the nail prior to application of the lacquer, a process that 
was not followed in this study. Nevertheless, historical data supports these findings with incidences of 
successful treatment very low, and relapse rates high, despite the extremely long treatment times 
involved. In addition, the relative effectiveness of the two marketed formulations in vivo seems to be 
depicted in the TurChub
TM
 in vitro model.  
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The purpose for deviating from the standard directions for use was given in the patient information 
leaflet for Penlac
®
 and Loceryl
®
 was to demonstrate the ability of the penetration enhancing system to 
alter the barrier properties of the nail after only a single application. Data from the present study 
confirms the ability of a thioglycolic acid/ hydrogen peroxide pre-treatment to significantly enhance the 
effectiveness of both Penlac and Loceryl across full thickness nail in vitro; even after only one 
application. A greater improvement in the efficacy of Penlac compared to Loceryl was seen in the 
presence of the penetration enhancer and there are at least two possible explanations for this. The 
most likely is due to the fact that Ciclopirox (Penlac) has a lower molecular weight than amorolfine 
(Loceryl) and as such has a greater inherent permeability making the effect of the enhancement 
more apparent. An alternative possibility is that the pre-treatment is helping to maintain ciclopirox in 
solution on the surface of the nail and thus sustaining drug absorption resulting in greater efficacy. 
Such results suggest that any potential formulation should be developed and optimised for the drug 
selected.  The increased rate of ungual permeation observed for both ciclopirox and amorolfine in the 
presence of the permeation enhancing system could lead to a significant decrease in required 
treatment time and combined with an increase in patient compliance result in an increase in overall 
successful treatment outcomes.  
 
Infected nail model 
The infected nail model was used to compare Penlac
®
 and Loceryl
®
 to a spray product containing 
terbinafine developed in-house and a range of controls. The terbinafine spray formulation was 
significantly better than Penlac
®
 and Loceryl
®
 at a 95% confidence level (p < 0.05) using infected 
cadaver nails. The terbinafine spray formulation (incorporating the enhancers) gave complete kill in all 
repeats of the sample, and levels of ATP recovered from the nails (5.4 ± 3.2% (mean ± SD) of 
infected control levels) were equivalent to negative control whereby no organisms were added to the 
nail (5.3 ± 1.6% of infected control levels). In comparison the spray vehicle (i.e. a placebo containing 
no terbinafine), Penlac
®
 and Loceryl
®
 all showed no statistically significant decrease (p > 0.05) in ATP 
levels recovered from the nails, compared to  infected controls which received no treatment (figure 3) 
(78.9 ± 32.8%, 87.4 ± 23.1% and 79.0 ± 32.8% of infected control levels respectively).  When the 
healthy volunteer distal nail sections were used Penlac
®
 (31.9 ± 1.7%) and Loceryl
®
 (24.0 ± 0.7%)  
both formulations showed a statistically significant decrease (p < 0.05) in  percentage ATP levels 
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compared to the infected control (100%) but the levels did not decrease to those seen in the negative 
untreated control (1.93 ± 1.37%).  
 
It is thought that the thioglycolic acid component of the pre-treatment system causes reduction of –S-
S- bonds in the keratin to –SH where the addition of hydrogen results in the cleavage of the 
disulphide bridge which in turn leads to the formation of cysteine amino acid molecules, as is known 
to happen in hair care products [36].   In hair care products it is well known that application of urea 
hydrogen peroxide results in the re-formation of the broken disulphide bridges [37], however in the 
nail previously reported data has shown that application of urea hydrogen peroxide following initial 
administration of thioglycolic acid actually causes a further increase in the permeability of the nail [35] 
thus suggesting that in the case of the nail the –S-S- bonds are not reformed in the same way as in 
the hair. One possible explanation for this phenomena is that as a result of the fairly high 
concentration and prolonged application (20h) of the thioglycolic acid, disulphide bonds do not reform 
because the initial cleavage of the bridges is damaging to the nail keratin structure resulting in a semi-
permanent (longer than 20h) reduction in the integrity of the nail barrier and therefore increased drug 
permeation.  
 
Although combination of the permeation enhancing system with all three active agents investigated 
resulted in increased permeation of all three agents and increased the apparent efficacy of each, as 
demonstrated by the infected nail model, the best results were observed when using terbinafine as 
the active agent. As such the increased effectiveness of terbinafine may not only be as a result of its 
enhanced ungual absorption but also because of its increased potency (minimum inhibitory 
concentration (MIC) (0.016 – 0.125 µg/ml)) compared to ciclopirox and amorolfine) (MICs of  0.25-2 
µg/ml and 0.04 – 0.063 µg/ml respectively)  
 
CONCLUSION 
The nail is a very difficult barrier to overcome when attempting to delivery drugs to the underside of 
the nail or the nail bed [3, 21, 38]. This is reflected in the low success rates and high relapse rates of 
the products currently available for the topical treatment of onychomycosis [11, 12]. This study has 
clearly demonstrated that the use of a novel permeation enhancing system which fundamentally alters 
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the chemical structure so that the rate of permeation of a range of antifungal agents is significantly 
increased. This proof of concept study involved the sacrificial termination of all samples at the end of 
the study and further work is required to understand the nature of the changes occurring in the nail 
structure and the length of duration of the effect. As demonstrated in this study this penetration 
enhancing system could potential be combined with the current topical treatments for onychomycosis, 
Penlac
®
 and Loceryl
®
, to create a single treatment with enhanced permeation of their antifungal 
agents (ciclopirox and amorolofine respectively).  As shown in this study a permeation enhancing 
system could also potentially be formulated into a nail lacquer or spray formulation containing 
terbinafine.  Terbinafine is the current gold standard oral treatment for onychomcosis, but has 
significant systemic side effects which limit its use in this indication, if terbinafine could be delivered 
topically in this way it would significantly reduce the chances of systemic toxicity.   
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FIGURE LEGENDS 
 
 
Figure 1. Four examples of typical zone of inhibition results observed in the TurChub® cell test 
system 
 
Figure 2: Comparison of zones of inhibition observed in the TurChub cell test system following 
application of the test systems to the nail surface (Figures are calculated as a percentage of the 
maximum possible zone of inhibition, Mean ± SEM, n = 6).  
 
 
Figure 3. Comparison of % ATP recovered compared to infected control (Mean ± SEM, n=5 with 
exception of ‘*’ where n=4, cell rejected after failing inter QC) following a single 1 l dose at t=0 and 
incubated for 7 days treatment 
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